Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial) - Sex-specific outcomes

Sep 29, 2026

Sex-specific analyses evaluate intravenous ferric carboxymaltose in patients with heart failure and iron deficiency within the FAIR-HF2 (DZHK05) trial framework. The research article describes trial outcomes reported by sex, focusing on how treatment effects may differ between men and women. Findings are presented in an academic format in European Journal of Heart Failure, with extensive multinational authorship and institutional affiliations, and includes a correction notice added on 06 November 2025.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

European Journal of Heart Failure (2025) 27, 2328–2342 RESEARCH ARTICLE doi:10.1002/ejhf.3742 Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes Mahir Karakas 1,2 *, Tim Friede3,4, Javed Butler5,6, Khawaja M. Talha7, Marius Placzek3,4, Thomas Asendorf3,4, Monika Diek8, Anna Nosko 1, Adriane Stas4,9, Stefan Kluge 1, Dominik Jarczak1, Geraldine DeHeer 1, Meike Rybczynski 10,11, Antoni Bayes-Genis 12, Michael Böhm 13, Andrew J.S. Coats 14, Frank Edelmann 15,16, Gerasimos Filippatos 17, Gerd Hasenfuß4,18, Wilhelm Haverkamp8, Mitja Lainscak19,20, Ulf Landmesser21,22,23, Iain C . Macdougall24, Bela Merkely25, Burkert M. Pieske26, Fausto J Pinto27, Tienush Rassaf28, Jennifer K. Visser-Rogers29, Giuseppe Rosano30,31,32,33, Maurizio Volterrani34,35, Stephan von Haehling4,18, Markus S. Anker21,22,23, Wolfram Doehner36, Hüseyin Ince26, Friedrich Koehler37,38,39, Gianluigi Savarese40, Muhammad Shahzeb Khan6,41, Ursula Rauch Kröhnert21,22,23, Tommaso Gori42,43, Teresa Trenkwalder44,45, Ibrahim Akin46,47, Christina Paitazoglou48, Iwona Kobielusz-Gembala49, Luca Kuthi25, Norbert Frey50, Manuela Licka50, Stefan Kääb51, Karl-Ludwig Laugwitz52,53, Piotr Ponikowski54, and Stefan D. Anker8 * 1 Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 2 Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK), Hamburg, Germany; 3 Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany; 4 Partner site Lower Saxony, German Centre for Cardiovascular Research (DZHK), Göttingen, Germany; 5 Department of Medicine, University of Mississippi Medical Centre, Jackson, MS, USA; 6 Baylor Scott and White Research Institute, Dallas, TX, USA; 7 Department of Cardiovascular Disease, Loyola University Medical Centre, Maywood, IL, USA; 8 Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany; Institute of Health Centre for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany; 9 Department of Medical Informatics, University Medical Centre Göttingen, Göttingen, Germany; 10Department of Cardiology, University Heart & Vascular Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 11 Partner Site Hamburg/Kiel/Lübeck, German Centre for Cardiovascular Research (DZHK), Hamburg, Germany; 12Heart Institute, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 13Department of Medicine III and HOMICAREM (Homburg Institute for CardioRenalMetabolic Medicine) Saarland University, Homburg, Germany; 14Heart Research Institute, Sydney, NSW, Australia; 15Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany; 16German Centre for Cardiovascular Research (DZHK) Partner site Berlin, Charité Universitätsmedizin, Berlin, Germany; 17Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 18Department of Cardiology and Pneumology, University Medical Centre Göttingen, Georg August University of Göttingen, Göttingen, Germany; 19Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia; 20 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 21Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Berlin, Germany; 22 Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany; 23 DZHK (German Centre for Cardiovascular Research), Partner site Berlin, Berlin, Germany; 24 Department of Renal Medicine, King’s College Hospital, London, UK; 25 Heart and Vascular Centre, Semmelweis University, Budapest, Hungary; 26 Division of Cardiology, Department of Internal Medicine

FAQs

What treatment is evaluated in this study?

The study evaluates intravenous ferric carboxymaltose for heart failure patients with iron deficiency.

Which trial is referenced for the results?

The results are reported within the FAIR-HF2 (DZHK05) trial.

What is the study’s main focus regarding patient groups?

The article focuses on sex-specific outcomes, comparing results by sex.

Sep 29, 2026

Uploaded by Chumphorn